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Abstract
Aims Recent clinical trials have proven gliflozins to be cardioprotective in diabetic and non‐diabetic patients. However, the
underlying mechanisms are incompletely understood. A potential inhibition of cardiac Na+/H+ exchanger 1 (NHE1) has been
suggested in animal models. We investigated the effect of empagliflozin on NHE1 activity in human atrial cardiomyocytes.
Methods and results Expression of NHE1 was assessed in human atrial and ventricular tissue via western blotting. NHE ac-
tivity was measured as the maximal slope of pH recovery after NH4
+ pulse in isolated carboxy‐seminaphtarhodafluor 1
(SNARF1)‐acetoxymethylester‐loaded murine ventricular and human atrial cardiomyocytes. NHE1 is abundantly expressed in
human atrial and ventricular tissue. Interestingly, compared with patients without heart failure (HF), atrial NHE1 expression
was significantly increased in patients with HF with preserved ejection fraction and atrial fibrillation. The largest increase in
atrial and ventricular NHE1 expression, however, was observed in patients with end‐stage HF undergoing heart transplanta-
tion. Importantly, acute exposure to empagliflozin (1 μmol/L, 10 min) significantly inhibited NHE activity to a similar extent
in human atrial myocytes and mouse ventricular myocytes. This inhibition was also achieved by incubation with the
well‐described selective NHE inhibitor cariporide (10 μmol/L, 10 min).
Conclusions This is the first study systematically analysing NHE1 expression in human atrial and ventricular myocardium of
HF patients. We show that empagliflozin inhibits NHE in human cardiomyocytes. The extent of NHE inhibition was comparable
with cariporide and may potentially contribute to the improved outcome of patients in clinical trials.
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Background
Gliflozins have been developed as oral antidiabetic drugs
acting via increased urinary glucose excretion by selective
inhibition of Na‐glucose contransporter 2 (SGLT2) in the renal
proximal tubules.1 Surprisingly, large clinical trials have
shown a reduced incidence of hospitalization for heart failure
(HF) and cardiovascular death in diabetic as well as
non‐diabetic patients treated with gliflozins. Numerous
potential mechanisms were proposed4 including direct
cardiac effects [inhibition of cardiac Ca/calmodulin‐
dependent protein kinase II (CaMKII)],5 effects on contractile
and myofilament function,6,7 up‐regulation of cardiac glucose
transporter 1 (GLUT1)8 as well as metabolic changes.9,10
However, the cardiac target for these drug effects remains
elusive, especially because cardiac SGLT2 expression is
negligible.5 Recently, empagliflozin has been shown to reduce
the activity of cardiac Na+/H+ exchanger 1 (NHE1) in mouse,
rat, and rabbit hearts,11,12 a mechanism of action, which
has repeatedly been suggested to be cardioprotective.13,14
However, to date, it was unclear if empagliflozin could also
inhibit NHE in human myocardium.
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Aims
We aimed at investigating the acute effect of empagliflozin
on NHE activity in isolated human cardiomyocytes and
characterizing NHE1 expression in human cardiac tissue of
patients with HF.
Methods
Between April 2019 and November 2019, patients undergo-
ing cardiac surgery at the University Hospital Regensburg
were prospectively tested for eligibility. Right atrial append-
age biopsies were collected during surgery. In addition, left
ventricular (LV) tissue of patients with LV hypertrophy and
normal systolic LV function [ejection fraction (EF) > 50%]
was collected from septum resections obtained during
surgical aortic valve implantation. Atrial and LV tissue was
also collected from explanted hearts of heart transplant
recipients. The study was approved by local ethics






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2 Baseline patient characteristics: ventricular tissue
LVH (N ¼ 5) HTX (N ¼ 5) P
Age (years), mean ± SD 65 ± 8 49 ± 15 0.07S
Male gender, N (%) 3 (60%) 5 (100%) 0.44F
LVEF, mean ± SD 65 ± 9 20 ± 6 <0.0001S
IVSd (mm), mean ± SD (N) 13.5 ± 2.1
(2)
8.3 ± 0.9 (4) 0.01S
Hypercholesterolaemia, N (%) 1 (20%) (4) 3 (60%) 0.52F
Arterial hypertension, N (%) 3 (60%) 3 (60%) 1.0F
Sinus rhythm, N (%) 5 (100%) 4 (80%) 1.0F
Atrial fibrillation, N (%) 0 (0%) 1 (20%) 1.0F
Paroxysmal 0 (0%) 1 (20%) 1.0
F
Persistent/permanent 0 (0%) 0 (0%) 1.0
F
Unspecified 0 (0%) 0 (0%) 1.0
F
Diabetes mellitus, N (%) 1 (20%) 0 (0%) 1.0F





Antidiabetic treatment, N (%) 1 (20%) 0 (0%) 1.0F
Dietetic treatment, N (%) 1 (20%) 0 (0%) 1.0F
Medical treatment, N (%) 0 (0%) 0 (0%) 1.0F
Insulin ± medical treatment, N
(%)
0 (0%) 0 (0%) 1.0F
HbA1c, haemoglobin A1c; HTX, patients with end‐stage heart fail-
ure undergoing heart transplantation; IVSd, interventricular sep-
tum thickness in diastole; LVEF, left ventricular ejection fraction;
LVH, patients with left ventricular hypertrophy and normal systolic
left ventricular function; SD, standard deviation.
Values are either the total number of patients (relative proportion
in parentheses), mean ± SD or median with interquartile range,
as indicated. If data were not available for all patients studied,
the number of patients used for analysis is given in parentheses.
Relative proportions always refer to the total number of patients
of the respective subgroup. P‐values are calculated using
two‐tailed Student’s t‐test (S) for continuous data or Fisher’s exact
test (F) for categorical data, respectively. The bold emphasis is ap-
plied to highlight statistically significant p‐values < 0.05.
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well as University of Göttingen, Lower Saxony, Germany) and
performed in accordance with the Declaration of Helsinki
(first released in 1964; most recent revision 2013). Patients
provided written consent prior to tissue donation.
Experiments with murine cardiomyocytes conformed to
Directive 2010/63/EU of the European Parliament, to the
‘Guide for the Care and Use of Laboratory Animals’ (Eighth
Edition, 2011) published by the US National Institutes of
Health, and to local institutional guidelines.
The NHE1 expression and activity were analysed using
western blotting and NH4
+ pulse method, respectively. For
detailed description of the experimental methodology, we
kindly refer to Supporting Information, Data S1.
Experimental data are presented as means ± standard
error of the mean and continuous clinical data as
means ± standard deviation. Statistics were based on the
number of patients or mice, respectively. Mixed effects
analysis with Holm–Sidak’s post hoc test, Wilcoxon
matched‐pairs signed‐rank test, and Brown–Forsythe and
Welch ANOVA test with two‐stage step‐up procedure of
Benjamini, Krieger, and Yekutieli was applied to test for
statistical significance as appropriate. Differences in
patients’ clinical baseline characteristics were analysed
using Pearson’s χ2 test and Fisher’s exact test for categori-
cal data and ANOVA, Student’s t‐test, or Kruskal–Wallis test
for continuous data, respectively. Bonferroni correction was
applied for multiple comparisons. All these tests were
performed in GraphPad Prism 8 or Stata/MP 13.0.
Two‐sided P‐values below 0.05 were considered statistically
significant.
Figure 1 NHE expression in human atrial and ventricular cardiomyocytes. (A) Original western blot for the assessment of NHE1 expression (~95 kD) in
human atrial appendages from patients without heart failure (NF SR), with heart failure with preserved ejection fraction in sinus rhythm (HFpEF SR),
HFpEF and atrial fibrillation (HFpEF AFib) as well as from explanted end‐stage failing hearts (HTX). (B) Analysis of mean densitometric values normalized
to glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH) showed a significant reduction of NHE1 expression in atrial appendages from patients with
reduced left ventricular ejection fraction (ejection fraction < 40%, N ¼ 4) compared with all other groups, while in patients with HFpEF and atrial fi-
brillation as well as in patients with end‐stage heart failure, atrial expression of NHE1 is significantly up‐regulated.
*
P < 0.05 vs. NF SR,
#
P < 0.05 vs.
HFpEF SR, ϮP < 0.05 vs. HFpEF AFib. Brown–Forsythe and Welch ANOVA test with two‐stage step‐up procedure of Benjamini, Krieger, and Yekutieli.
(C) Original western blot for the assessment of NHE1 expression (~95 kD) in human ventricular myocardium from patients with left ventricular hyper-
trophy and normal systolic left ventricular function (LVH) and from explanted end‐stage failing hearts (HTX). (D) In ventricular myocardium of end‐stage
failing hearts, NHE1 expression is significantly up‐regulated compared with ventricular myocardium from patients with left ventricular hypertrophy
(N ¼ 5 vs. 5). Two‐tailed Student’s t‐test.
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Results
Right atrial tissue of 52 patients with coronary and/or valvular
heart disease undergoing elective cardiac surgery as well as
of 4 patients with end‐stage ischaemic heart disease under-
going cardiac transplantation was analysed for atrial NHE1
expression (Table 1). These patients represent a typical
cohort of patients with heart disease. They were 66 ± 11
(mean ± standard deviation) years old and predominantly of
male gender (91%). Approximately one‐third of the patients
suffered from diabetes mellitus, and 86% had arterial
hypertension. Forty‐one per cent were diagnosed with HF,
requiring signs and symptoms. Seven per cent exhibited
severely reduced left ventricular ejection fraction (LVEF)
[heart failure with reduced ejection fraction (HFrEF),
EF < 40%, transplanted patients not included]. Fifteen (27%)
patients were diagnosed with HF with preserved ejection
fraction (HFpEF) (LVEF > 50) additionally requiring elevated
N‐terminal pro‐brain natriuretic peptide levels and either LV
hypertrophy (LV mass index ≥ 115 g/m2 for male patients
and ≥95 g/m2 for female patients), left atrial enlargement
(left atrial volume index> 34mL/m2), or diastolic dysfunction
according to current guidelines. The majority of patients were
in sinus rhythm (SR; 89%), while 11% were diagnosed with
atrial fibrillation (AF).
In addition, LV tissue was obtained from patients with LV
hypertrophy and normal systolic LV function (EF > 50%)
undergoing aortic valve replacement surgery as well as
from end‐stage failing hearts explanted during cardiac
transplantation (Table 2).
We first aimed at systematically analysing NHE1 expression
in human atrial appendage biopsies of 56 patients. Figure 1A
shows original western blots and mean data. A strong expres-
sion was observed at ~95 kD (predicted molecular weight:
90 kD15) (Figure 1A). Interestingly, there was no difference
in atrial NHE1 expression in HFpEF patients with SR compared
with non‐failing control hearts [mean densitometric values
normalized to glyceraldehyde‐3‐phosphate dehydrogenase
(GAPDH): 2.17 ± 0.09 vs. 2.07 ± 0.18; NF SR vs. HFpEF SR,
N ¼ 33 vs. 10; P ¼ 0.11]. In contrast, HFpEF patients suffering
from AF exhibited a significantly increased atrial NHE1 expres-
sion (mean densitometric values normalized to GAPDH:
2.63 ± 0.09; N ¼ 5, P vs. HFpEF SR ¼ 0.004), which was only
surpassed by dramatically increased atrial NHE1 expression in
patients with end‐stage HF (mean densitometric values
normalized to GAPDH: 3.23 ± 0.24; N ¼ 4, P vs. HFpEF
SR ¼ 0.002) (Figure 1B). On the other hand, atrial NHE1
expression was slightly decreased in less sick HFrEF patients
with SR (mean densitometric values normalized to GAPDH:
1.73 ± 0.08; N ¼ 4; P vs. NF SR ¼ 0.002) (Figure 1B). In
accordance with atrial data, ventricular NHE1 expression
was significantly increased in patients with end‐stage HF
compared with patients with LV hypertrophy and normal LV
function (mean densitometric values normalized to GAPDH:
0.64 ± 0.08 vs. 0.34 ± 0.06; N ¼ 5 vs. 5; P ¼ 0.019) (Figure
1C,D).
Next, we evaluated the effect of empagliflozin on NHE ac-
tivity. We first investigated isolated mouse ventricular
myocytes under normoglycemic conditions. After calibration
of SNARF1 fluorescence (F580/F640) using the ‘nigericin–high
K+ approach’ (see Supporting Information, Data S1 and Figure
2A,B), NHE function was assessed as the maximal slope of pH
recovery following a 10 min NH4
+ pulse (Figure 3A–C). Inter-
estingly, exposure to empagliflozin (1 μmol/L) significantly
slowed the pH recovery kinetics after NH4
+ pulse consistent
with inhibition of NHE function. The slope of pH recovery
was (0.152 ± 0.017 pH/min vs. 0.085 ± 0.013 pH/min veh
vs. Empa, N ¼ 10 vs. 11, P < 0.05) comparable with the effect
of the selective NHE inhibitor cariporide (10 μmol/L)
Figure 2 Calibration experiments for the assessment of Na+/H+ ex-
changer activity in isolated ventricular cardiomyocytes. (A) Original cali-
bration experiment measuring SNARF1 fluorescence intensity (at 580
and 640 nm emission wavelength) in response to defined pH solutions.
(B) Resulting calibration curve applying a non‐linear least squares regres-
sion with the means (± SEM) of F580/F640 ratios plotted against intracellu-
lar pH.
Empagliflozin inhibits human cardiac NHE 5
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.13024
(0.054 ± 0.010 pH/min, N ¼ 5, P < 0.05 vs. veh) (Figure 3B,C).
This is in accordance to previously published data in mice,
rats, and rabbits.11,12
In a second step, we applied this experimental protocol to
our human atrial myocytes and were able to induce a pH re-
covery following a 10 min NH4
+ pulse. Figure 4A shows the
original registration of SNARF1 fluorescence in a human atrial
cardiomyocyte. The pH recovery after the NH4
+ pulse was slow
but still readily detectable (Figure 4A). Importantly, here, we
show for the first time that exposure to empagliflozin
(1 μmol/L) almost completely abolished the pH recovery
consistent with inhibition of NHE function in isolated
human atrial myocytes (0.039 ± 0.008 pH/min vs.
0.021 ± 0.006 pH/min, N ¼ 9 vs. 9, P ¼ 0.0195) (Figure 4A,
B). Intriguingly, the inhibition was of similar magnitude as in
the presence of the selective NHE inhibitor cariporide
(10 μmol/L) (0.036 ± 0.013 pH/min, N ¼ 6, P ¼ 0.0313)
(Figure 4A,C).
Figure 3 Na+/H+ exchanger (NHE) activity in isolated murine ventricular cardiomyocytes. (A) Original registration of SNARF1 fluorescence (after cali-
bration) before, during, and after NH4Cl‐dependent acidification in isolated mouse ventricular myocytes. NHE activity was assessed as the maximal
slope of pH recovery after NH4Cl pulse (within rectangle). (B) Averaged pH recordings of the pH recovery phase. (C) Derived maximal slope in ΔpH/
min (shown as mean ± standard error of the mean, scatter and spaghetti plots). Compared with vehicle (dimethyl sulfoxide), NHE activity was signif-
icantly reduced in the presence of either empagliflozin (Empa, 1 μmol/L) or cariporide (10 μmol/L). The number of mice/cells were 10/12 (dimethyl
sulfoxide), 11/17 (empagliflozin), or 5/7 (cariporide).
*
P < 0.05 vs. vehicle, mixed effects analysis with Holm–Sidak’s post hoc correction.
Figure 4 Na+/H+ exchanger (NHE) activity in isolated human atrial cardiomyocytes. (A) Original registrations of SNARF1 fluorescence calibrated to in-
tracellular pH in isolated human atrial cardiomyocytes. NHE activity was assessed as the maximal slope of pH recovery after NH4Cl pulse. The derived
maximal slope (in ΔpH/min) is shown as scatter and spaghetti plots in the presence of (B) either vehicle (veh) or empagliflozin (Empa, 1 μmol/L) and (C)
either vehicle or cariporide (10mmol/L). Compared with veh (dimethyl sulfoxide), NHE activity was significantly reduced in the presence of either Empa
or cariporide. The number of patients were 9 (veh) vs. 9 (Empa) and 6 (veh) vs. 6 (cariporide). Wilcoxon matched‐pairs signed‐rank test.
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Conclusions
We show here that atrial NHE1 expression was significantly
increased in HFpEF patients with AF (but not SR) and even
more so in patients with end‐stage HF undergoing heart
transplantation (even in SR) but not in less sick HFrEF
patients. Importantly, we are the first to show that
empagliflozin inhibits human NHE suggesting a mechanistic
link to the clinical benefits observed in clinical trials.
At first glance, it seems counter‐intuitive that NHE1 ex-
pression was not increased in HFpEF with SR and was even
modestly reduced in HFrEF patients. However, it is unclear
if atrial myocytes of HFpEF patients with SR or HFrEF patients
had indeed abnormal contractile function, which may be a
prerequisite for increased NHE1 expression. Although both
patient cohorts showed markedly enlarged atrial dimensions
(Table 1), which are usually accompanied by impaired con-
tractile function, we did not directly measure atrial contractil-
ity. Moreover, the extent of contractile dysfunction may also
be important. We show here that atrial NHE1 expression was
significantly increased in HFpEF patients with AF in contrast
to HFpEF patients with SR, which may be a consequence of
the larger impairment of atrial contractile function in AF. In
addition, the four patients who fulfilled the criteria for HFrEF
had less impaired LVEF compared with patients with
end‐stage HF (mean LVEF 35 ± 1% vs. 20 ± 7%; Table 1), also
indicating that the severity of contractile dysfunction may be
important for regulation of NHE1 expression. This notion is
further supported by our observation that NHE1 expression
in ventricular myocardium of patients with end‐stage HF is
markedly up‐regulated compared with ventricular myocar-
dium of patients with LV hypertrophy and normal LV
function.
Besides these considerations, NHE1 expression may be not
even directly correlated to activity. Previous studies that have
made use of smaller patient cohorts showed a discrepancy
between NHE expression and activity in HF.16 They
suggested that post‐translational modifications, such as
kinase‐dependent phosphorylation (e.g. by CaMKII),17–19
might be responsible for increased NHE activity in HF, which
was reported by numerous studies.16,20 Irrespective of
expression levels, increased NHE activity appears to play an
important role in the pathophysiology of hypertrophy and
HF. Studies using cardiac cells, for instance, have consistently
demonstrated that NHE inhibitors block hypertrophic
responses to various stimuli.21 Moreover, inhibition of NHE
has been shown to reduce cardiac hypertrophy, fibrosis, re-
modelling, and systolic dysfunction in experimental models
of HF.13,14 The precise mechanism for NHE1 involvement in
hypertrophy or HF remains to be determined. Interestingly,
NHE1 activation has been shown to result in accumulation
of intracellular Na, which reduces/reverses the driving force
for the Na/Ca exchanger‐mediated Ca efflux and leads to
intracellular Ca overload and contractile dysfunction.14,20,22
In addition, intracellular alkalosis, which may also be a
consequence of NHE1 activation, has been shown to
increase myofilament Ca responsiveness and thus impair
diastolic function.23 Indeed, we have shown recently that
empagliflozin reduced myofilament Ca sensitivity and im-
proved diastolic dysfunction in human myocardium.6 Accord-
ingly, either the reduction of Na entry or normalization of
intracellular pH by empagliflozin‐dependent NHE1 inhibition
may both ameliorate contractile dysfunction in HF. Interest-
ingly, a recent study addressing the cardioprotective mecha-
nisms of empagliflozin using deep learning in silico analyses
with in vivo validation reported NHE1 blockade as the most
robust possible underlying mechanism of action.24 However,
if empagliflozin directly inhibits NHE1 or if inhibition of NHE
activity is rather a consequence of upstream alterations in
cellular Na load, intracellular pH or interference with
post‐translational modifications (e.g. by inhibition of CaMKII5)
remains elusive. In conclusion, our data add important novel
insights into the potential mechanisms mediating the
cardioprotective effect of empagliflozin observed in
large‐scale clinical trials.2,3
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